BioSpace News Archive

Cognoptix, a leading diagnostics company dedicated to the early detection of Alzheimer’s disease (AD), announces two appointments to its senior management team. Dr. Carl H. Sadowsky, MD will serve as the company’s new Chief Medical Officer (CMO) and Mike Kaswan, MBA will be Cognoptix’s Chief Financial Officer (CFO).

Align Technology, Inc. (Nasdaq: ALGN) announced today that the Company will report fourth quarter and 2020 financial results on Wednesday, February 3, 2021, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Company’s website at http://investor.aligntech.com.

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Virtual BioConnect Conference that will be available on Monday, January 11, 2021 at 6:00 am ET. A webcast of the presentation can be accessed on the company’s website at http://ir.zosanopharma.com/events-presentations . The archi

Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter intellectual property (IP) connecting People and Things, today announced that its patent portfolio has grown 50% year-over-year, now comprising over 300 issued and pending U.S. and foreign patents – of which over 150 are related to Resonant’s groundbreaking 5G XBAR® technology.

Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2021 of $1.01 per share on the company’s common stock. The dividend is payable on March 9, 2021 to shareholders of record at the close of business on February 23, 2021 . The ex-dividend date i

Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to report positive signs of clinical, endoscopic and histologic response in subjects participating in Stage 1 of their Phase 2 RESTORE trial for the treatment of patients with moderate-to-severe Crohn’s disease. These posi

BioAgilytix Labs is pleased to announce the appointment of Marc Westermann to its commercial leadership team as Vice President of Business Development Europe. Westermann brings more than 25 years of senior corporate executive and commercial operations experience to BioAgilytix. He has a proven track record of leading performance wit

Bryn Pharma, LLC (“Bryn” or the “Company”), a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced that results from its multi-dose study of BRYN-NDS1C (bi-dose epinephrine nasal spray), have been accepted for presentation at the 2021 American Acad

ImmunityBio, a privately-held immunotherapy company, today announced the results of a highly detailed computer-based molecular dynamics (MD) simulation, conducted in collaboration with Microsoft Corporation, that allowed visualization of the behavior of the SARS-CoV-2 “spike” protein.

EV Biologics Corp (OTC:YECO) today announced that it has completed all its filings on OTC Markets with its 10K, 2020 filing today. The Company expects to become Pink Current within the next few weeks, then apply for a OTCQB listing. For the Company, being current allows the majority of brokers to trade in our shares, whereas before only online brokers could buy or sell the security.